Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, TRI, FDA

Tarsius Pharma Announces FDA Acceptance of IND Application for TRS01

TEL-AVIV, Israel, Sept. 24, 2019 /PRNewswire/ -- Tarsius Pharma today announced the acceptance of its Investigational New Drug (IND) application for TRS01 by the U.S. Food and Drug Administration (FDA).

The company is developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases. TRS was developed to 're-engineer' the immune system, and approaches inflammatory diseases from within the system. This IND acceptance will enable Tarsius to initiate enrollment in its planned Phase I/II clinical trial of TRS01.

The planned study is a multi-center, randomized, placebo-controlled dose-ranging study in patients with ocular inflammation following cataract surgery. This study is designed to determine the safety profile of TRS01, the recommended dose, and preliminary evaluation of the potential effect of TRS01 in ocular inflammation.

"The FDA's acceptance of our IND for TRS01 is a critical milestone for patients, as we are now one step closer to bring a new treatment that will transform the lives of people with serious blinding diseases". Said Dr. Daphne Haim-Langford, Founder and CEO, Tarsius Pharma. "This is an exciting time for us, and we look forward to embarking on our next chapter as a clinical stage company". Said Zohar Milman, Tarsius COO.

Ocular inflammatory diseases impose a significant medical and economic burden on society, affecting hundreds of million people worldwide and posing severe risks of vision loss and blindness.

In more than 50 years, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences.

The TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases. Untreated, these diseases can have devastating effects, and may eventually lead to blindness.

About Tarsius Pharma

Tarsius Pharma was established in 2016 and is focused on developing innovative therapeutic solutions to prevent blindness. Tarsius is backed by Sun Pharmaceuticals, a global pharmaceutical company, as well as investments by private investors and family offices. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 879598.  

For more information please contact:
Tel: +1-914-3392556

SOURCE Tarsius Pharma

These press releases may also interest you

at 08:35
Phunware, Inc. (the "Company"), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, today announced that it will be attending and presenting at the Small Business Expo in...

at 08:35
The Konka Group, a leading digital home entertainment manufacturer and one of the top five TV brands in China, today announced a major brand expansion into the North American market. With 35 years of experience as a prime manufacturer, developing,...

at 08:35
Blockchain technology platform for the precious metals mining industry, Karuschain, announced recently that Herbert R. Sim, commonly known as "The Bitcoin Man", will be joining its team as an investor and advisor. This news comes as a follow-up from...

at 08:31
Tripleseat, the leading web-based sales and event management platform, released today five recommended venues across San Francisco to host a last-minute company holiday party. If your boss put you in charge of planning the company's holiday party,...

at 08:30
Allied Market Research recently published a report, titled, "Self-Driving Bus Market by Level of Automation (Level 3, Level 4, and Level 5) and Component (Hardware, Software, and Services): Global Opportunity Analysis and Industry Forecast,...

at 08:30
According to the new market research report "IoT in Aviation Market by End Market (Airports, Airlines, MROs, Manufacturers), Application (Ground Operations, Passenger Experience, Asset Management, Air Traffic Management), Component, Region - Global...

News published on 24 september 2019 at 10:00 and distributed by: